Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.
BACKGROUND
Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described.


OBJECTIVE
To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity.


METHODS
Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity.


RESULTS
Between 1/2006 and 9/2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury.


CONCLUSIONS
Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.
Vuppalanchi
R
R
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Hayashi
P H
PH
Chalasani
N
N
Fontana
R J
RJ
Bonkovsky
H
H
Saxena
R
R
Kleiner
D
D
Hoofnagle
J H
JH
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013876:Thiophenes / Q000009:adverse effects*
D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride
Hum Psychopharmacol. 2009 Jul;24(5):401-8
19526453
Clin Ther. 2005 Aug;27(8):1126-43
16199241
Clin Gastroenterol Hepatol. 2006 Jul;4(7):912-7
16797245
Curr Drug Saf. 2008 May;3(2):143-53
18690992
Am Rev Respir Dis. 1978 Sep;118(3):461-6
707874
Drug Saf. 2009;32(1):55-68
19132805
J Clin Psychiatry. 2003 Dec;64(12):1465-75
14728109
J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S34-9
14562856
Am Rev Respir Dis. 1986 Oct;134(4):666-8
3767121
Am Rev Respir Dis. 1978 Jun;117(6):991-1001
666111
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
15939837
Clin Pediatr (Phila). 2001 May;40(5):243-8
11388672
Curr Med Res Opin. 2007 Jan;23(1):175-84
17257478
Hepatology. 2010 Jun;51(6):2117-26
20512999